Frazier Life Sciences Raises Over $630 Million for Evergreen Public Fund

Frazier Life Sciences (FLS), a healthcare investment firm, has successfully closed on more than $630 million in capital commitments for its evergreen Public Fund. The fundraise involved both new and existing investors, resulting in oversubscription.

The FLS Public Fund, established as a dedicated vehicle three years prior, has raised about $1.7 billion under the direction of Albert Cha, Jamie Brush, Jamie Topper, and Patrick Heron. This long-only Public Fund is designed to navigate volatility and liquidity in small- and mid-cap public biotech companies, with the flexibility to invest in later stage private companies through crossover financings. Notably, several of the Fund's major positions, such as Sierra Oncology, Chinook Therapeutics, and Alpine Immune Sciences, have been acquired by prominent pharmaceutical companies.

Frazier Life Sciences, with over $3.9 billion in managed capital, invests globally in both private and publicly traded companies focused on innovative biopharmaceuticals. The firm's team, comprising over 40 professionals, is deeply experienced in biopharmaceuticals and is primarily located in various key cities.